Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report) saw strong trading volume on Wednesday . 1,022,846 shares changed hands during trading, a decline of 15% from the previous session's volume of 1,198,851 shares.The stock last traded at $0.59 and had previously closed at $0.67.
Elite Pharmaceuticals Stock Down 0.2%
The stock's fifty day moving average is $0.56 and its 200-day moving average is $0.51. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.27 and a quick ratio of 1.90.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last released its quarterly earnings data on Monday, June 30th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. The firm had revenue of $32.00 million for the quarter. Elite Pharmaceuticals had a negative return on equity of 6.92% and a negative net margin of 25.70%.
Elite Pharmaceuticals Company Profile
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
See Also
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
